Valitacell, an Irish biotechnology SME, has been selected by as one of 11 high potential global start-ups to join the prestigious health tech accelerator programme Startup Creasphere.
The Startup Creasphere innovation programme matches global pharmaceutical partners including Roche, Sanofi and Lonza with the World’s most innovative and disruptive health tech start-ups.
The global healthcare giant Lonza has chosen to collaborate with Valitacell as their chosen high potential start up for the 3-month programme.
Commenting on the partnership, Dr. Stephanie Davies, Head of Cell Therapy at Valitacell said
“Valitacell is delighted to have been chosen by Lonza for this 3-month accelerator programme and we look forward to working with Lonza to transform healthcare together”.